SI-BONE, Inc.: management transactions · United States · SEC (Form 4)

About SI-BONE, Inc.

SI-BONE, Inc. is a U.S.-based medical device company listed on the Nasdaq in the United States. The company focuses on sacropelvic and musculoskeletal disorders, with a particular emphasis on sacroiliac (SI) joint dysfunction and related fusion procedures. Founded in 2008 in Delaware and headquartered in Santa Clara, California, SI-BONE built its franchise around a clinically differentiated implant platform and a strong evidence-based positioning in a niche segment of orthopedic surgery. Its early leadership came from the iFuse system, a minimally invasive, triangular implant designed for SI joint fusion, which helped establish the company as an early mover in this category. ([investor.si-bone.com](https://investor.si-bone.com/static-files/56c626d7-ed89-4866-8e5e-a4fa04e47f7a?utm_source=openai)) From an operating perspective, SI-BONE sells procedural solutions to surgeons, hospitals, and ambulatory care providers, rather than operating as a broad orthopedic conglomerate. Its product portfolio now extends beyond the original iFuse platform and includes iFuse-3D, iFuse TORQ, iFuse Bedrock Granite, and iFuse INTRA, among others. This line expansion is important strategically: management has been repositioning the company from a single-product story toward a broader “compromised bone” solutions platform that can address additional clinical use cases in the pelvis, trauma, and spine-adjacent segments. ([investor.si-bone.com](https://investor.si-bone.com/static-files/56c626d7-ed89-4866-8e5e-a4fa04e47f7a?utm_source=openai)) Competitively, SI-BONE’s moat is based on first-mover advantage, a long clinical track record, surgeon education, and the company’s accumulated regulatory and reimbursement experience. In a specialty market where physician adoption and payer coverage are critical, SI-BONE has emphasized published clinical data, FDA clearances, and continued product iteration as sources of differentiation. The business remains primarily U.S.-driven, but it has also been expanding internationally, including launches in Europe and broader commercial activity outside the U.S. ([investor.si-bone.com](https://investor.si-bone.com/news-releases/news-release-details/si-bone-inc-announces-publication-5-year-follow-data-ifuse?utm_source=openai)) Recent developments have been supportive of the growth narrative. In 2025, SI-BONE reported strong revenue growth and highlighted improving profitability metrics, alongside favorable reimbursement progress. The company also continued to broaden its portfolio with new product launches and line extensions, while announcing a distribution agreement with Smith+Nephew to improve market access for certain solutions. For equity investors, SI-BONE is best viewed as an innovation-led, specialty medtech company with a focused franchise, a growing international footprint, and multiple execution catalysts tied to product adoption, reimbursement, and commercial expansion. ([investor.si-bone.com](https://investor.si-bone.com/news-releases/news-release-details/si-bone-inc-reports-record-financial-results-fourth-quarter-2025/?utm_source=openai))